PNC-27 Peptide: A Novel Synthetic Anti-Cancer Therapeutic Targeting Membrane HDM-2
Exploring the selective power of synthetic peptides in the fight against cancer, focusing on precise cellular targets.
Get a Quote & SampleProduct Core Value
PNC-27 Peptide
PNC-27 is a cutting-edge synthetic peptide with a unique mechanism designed to combat cancer. It selectively targets the HDM-2 protein present on the membranes of cancer cells. By binding to HDM-2, PNC-27 induces the formation of transmembrane pores, leading to the lysis and death of cancer cells. Crucially, this process is p53-independent and does not affect normal cells, offering a promising avenue for targeted cancer therapy.
- Discover the power of synthetic anti cancer peptide technology with PNC-27, a revolutionary approach to oncology.
- Understand the PNC-27 peptide mechanism of action, which involves precise targeting of HDM-2 for maximum therapeutic effect.
- Explore how PNC-27 cancer treatment offers a novel solution, distinguishing itself through selective cell killing.
- Learn about the advantages of HDM-2 targeting peptide technology and its role in developing next-generation cancer therapies.
Product Advantages
Unparalleled Selectivity
PNC-27 demonstrates remarkable selectivity, effectively inducing necrosis in cancer cells while sparing healthy cells, a key benefit of its HDM-2 targeting peptide mechanism.
Novel Necrosis Pathway
Unlike traditional therapies, PNC-27 leverages a p53-independent pathway to induce tumor cell necrosis, offering a new strategy for patients with various cancer types.
Broad Applicability
Research suggests PNC-27 is effective against a range of cancers, including various forms of leukemia, highlighting its potential as a versatile peptide treatment for cancer.
Key Applications
Cancer Therapy Development
As a synthetic anti cancer peptide, PNC-27 is a crucial component in the development of targeted oncology treatments.
Leukemia Research
Investigating the PNC-27 peptide mechanism of action in leukemia offers insights into novel treatment strategies for blood cancers.
Targeted Drug Delivery
The HDM-2 targeting peptide approach of PNC-27 serves as a model for developing precise drug delivery systems in cancer therapy.
Oncology Drug Discovery
Exploring peptide induced necrosis cancer pathways, like those involving PNC-27, accelerates the discovery of next-generation cancer drugs.
Related Technical Articles & Resources
Why Choose Us?
Leverage our expertise and state-of-the-art infrastructure to accelerate your journey from discovery to commercial success.
Global Experience
With 20 years of R&D, manufacturing, and sales experience, we proudly serve clients across 60 countries and regions worldwide.
Advanced Facilities
Our in-house R&D laboratory, pilot platform, and large-scale production workshop are equipped to meet the audit requirements of global customers.
Seamless Scalability
We facilitate a perfect transition from small-scale lab requirements (grams) to full commercialization (hundreds of tons).